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T cell aging: naive but not young
 
Janko Nikolich- ugich Z ˇ
 
The immune system exhibits profound age-related changes, collectively 
termed immunosenescence. The most visible of these is the decline in protective 
immunity, which results from a complex interaction of primary immune 
defects and compensatory homeostatic mechanisms. The sum of these changes 
is a dysregulation of many processes that normally ensure optimal immune 
function. Recent advances suggest that old mice can produce fully functional 
new T cells, opening both intriguing inquiry avenues and raising critical 
questions to be pursued.
 
Infection, immunity, and aging
 
Immune aging manifests itself at several
levels, from the whole organism to indi-
vidual cells. At the organismal level, an
age-associated increase in susceptibility
to infectious diseases is well established.
Morbidity and mortality from numerous
viral (influenza, Varicella-Zoster, herpes
simplex virus-1, and poxviruses) and
bacterial (pneumococci; 
 
Escherichia coli
 
,
 
Salmonella
 
) diseases, including some no-
table  emerging pathogens (West Nile
virus [WNV] and SARS-inducing coro-
navirus) is increased in elderly humans
and old animals (for review see refer-
ences 1–3). These pathogens use distinct
ports of entry and induce distinct pathol-
ogies that affect numerous organ systems
(such as the skin, respiratory, circulatory,
urinary, central nervous system, etc.),
suggesting a decline and dysregulation of
many processes that normally lead to ef-
fective immunity (1, 2). Although it is
likely that functional and structural al-
terations in both the entry sites and the
target organs used by these pathogens
facilitate age-related susceptibility to
some infections (for example, impaired
barrier function), there is no doubt that
the dysregulation of immunity also plays
a central and critically important role in
this process. Accordingly, responsiveness
to vaccination in the elderly is also
substantially diminished, and vaccine-
induced protection is suboptimal.
At the cell population level, involu-
tion of the primary lymphoid organs
and defects in the production of early
lymphoid precursors severely impact
the immune system. Indeed, according
to recent reports, even the generation
of the earliest defined lymphoid pre-
cursors is diminished in aging (for re-
view see references 4 and 5). The other
decisive factor is the lifelong encounter
of the immune system with both acute
and chronic pathogens. Recent evi-
dence suggests that persisting pathogens
are very important in modulating the
numbers, function, and homeostasis of
T cell subsets as they result in an ever
increasing fraction of T cells that are
continuously or intermittently stimu-
lated (for review see reference 6).
Finally, at the individual cell level,
the fundamental processes affected by
aging include both the innate and adap-
tive arms of the immune response. Spe-
cifically, macrophage activation, DC
migration, follicular DC function, and
Toll-like receptor–mediated activation
were all found to be impaired or dys-
regulated to some degree (for review
see references 5 and 7). Likewise, anti-
gen presentation, although still insuffi-
ciently investigated, has been reported
to be decreased (8). Constitutive cy-
tokine secretion is generally regarded as
elevated, whereas that in response to
antigen or pathogen stimulation is gen-
erally reduced (9). Specifically, interleu-
kin (IL)-2 secretion by stimulated naive
T cells is reduced, and there is dysregu-
lation of both nonimmune and immune
interferon and IL-6 production. B cell
and, in particular, T cell function is
heavily altered. Germinal center forma-
tion is reduced, antibody responses are
delayed and blunted, and antibody af-
finity (and affinity maturation) is im-
paired (for review see reference 10).
Similarly, T cell receptor and costimula-
tory signaling pathways are blunted, se-
cretion of some cytokines (chiefly IL-2)
by stimulated naive T cells is drastically
reduced, and there is an accumulation
of nonfunctional, possibly replicatively
senescent T cells (for review see refer-
ences 1, 4, and 11). Some of the defects
in aging T cells are listed in Table I.
Presently, our understanding of the
mechanisms leading to immune aging
remains incomplete. Nevertheless, ma-
jor advances made in the last couple of
years, including two new studies by
Eaton et al. (12) and Haynes et al. (13),
have helped define many of the age-
related defects in the T and B cell com-
partments. One of these studies showed
that in response to nitrophenyl-pigeon
cytochrome C, defects in T cell cognate
help primarily and dominantly affect B
cell immunity in old mice, and that
transfer of young T cells into aged mice
largely normalizes antibody production
(12). Transfer of old T cells into young
animals yielded poor B cell responses
and one suspect in this decline appears
to be diminished expression of CD40
ligand (12). Although this stresses the
importance of T cell senescence and al-
though I will continue to discuss T cells
in the remainder of this article, one
should be mindful that other primary
defects upstream of T cells may very
well exist and be very important.
 
T cell senescence and homeostasis—half 
full or half empty?
 
Amongst the most important and excit-
ing advances were those regarding T
cell homeostasis. T cells can sense the
presence or the absence of sufficient
numbers of other T cells around them
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and adjust their division rate and
numbers  accordingly. Thus, in a lym-
phopenic situation, massive proliferation
of existing (or transferred) T cells occurs
to compensate for the low number of
preexisting T cells. Once the cell num-
bers reach a given level, the signal for
proliferation is likely exhausted or turned
off, and proliferation is terminated.
I shall discuss naive and memory T
cell homeostasis separately (14) in fur-
ther deliberations, although the two
compartments may not be as indepen-
dent as previously believed (at least
CD8 memory T cells seem to cross-
inhibit proliferation and/or repopula-
tion of the periphery by naive cells; ref-
erences 5 and 15).
In a steady-state situation, where
new (naive) T cells are constantly pro-
duced by the thymus, division rates are
constant. Murine recent thymic immi-
grants (RTE) populate the periphery
and are exempt from competition with
the preexisting naive T cell pool for
about 3 wk (16). Given the estimated
rate of 2 
 
  
 
10
 
6 
 
RTE/day in a mouse,
the same number of T cells needs to be
lost on a daily basis to make space for
the newcomers. Moreover, as the RTE
proliferate in the periphery, it is likely
that more cells need to be lost from the
preexisting pool. Most, if not all, cells
dying in this situation would also be na-
ive. Otherwise, the rest of the naive
pool divides very slowly until (and un-
less) stimulated by a cognate antigen or
by a lymphopenic environment. Mem-
ory T cells, by contrast, are self-renew-
ing in the periphery and their active cy-
cling (about once a week) is offset by an
equivalent cell loss from the memory T
cell subset. T cell receptor (TCR) stim-
ulation (for naive cells at least) and the
cytokines IL-7 and IL-15 (for both na-
ive and memory cells) provide critically
important trophic signals that maintain
viability and division rate, although
some aspects of this regulation remain
under investigation (for review see ref-
erence 15). In an empty or partially de-
pleted compartment, both memory and
naive T cells sense the void and begin
proliferating, again driven by signals
from the TCR, IL-7R, and IL-15R
(for review see reference 15). This
homeostatic proliferation stops once T
cells fill the compartment. In the most
simplistic sense, filling and emptying of
T cell compartments at a molecular
level could simply mean sensing a sur-
plus or a relative lack of the homeostatic
cytokines IL-7 and IL-15.
Regardless of the exact molecular
meaning of the void, changes in supply
and demand of naive T cells set the
stage for the most profound changes in
aging. Thymic production declines at
least 10-fold by the time of puberty;
therefore, fewer naive RTE will mean
higher proliferation of the remaining
naive T cells. Meanwhile, these naive T
cells are being depleted over a lifetime
of encounters with acute and, even
more importantly, chronic persisting
pathogens. This leads to a lifelong accu-
mulation of memory cells that appear to
be well preserved in aging (5, 17, and
unpublished data) and that may impair
repopulation and/or homeostatic pro-
liferation by naive cells (5 and unpub-
lished data). Simultaneously, IL-7 levels
could be reduced with age (18), poten-
tially affecting maintenance and viabil-
ity of naive cells. IL-2 production is di-
minished and this cytokine is critically
important in the elimination of ex-
panded T cells in the contraction stage
of the immune responses (19), poten-
tially leading to further accumulation of
memory cells. It is therefore not sur-
prising that the naive to memory T cell
ratio decreases, often severely, with ag-
ing. Accordingly, the glass (the naive T
cell compartment) looks worse than
half-empty from that perspective.
 
Of time and clocks
 
That the glass is actually at least half-full
is a testament to the resilience of T cell
homeostasis. In fact, the situation would
be utterly dismal were it not for the
homeostatic and compensatory mecha-
nisms that ensure normal function of T
cells into adulthood and early senes-
cence. At present, we do not possess
quantitative information on just how
elastic and active these mechanisms re-
ally are. What we know more about are
the limits of their action. Thus, lympho-
cytes can divide many times in response
to antigen and in response to homeo-
static stimuli, and although these cells are
equipped with mechanisms to allow for
intense division (for example, the in-
duction of telomerase; reference 20),
that capacity may not be infinite (11).
 
Table I.
 
Some of the known or suspected defects in T cell senescence
 
Affected cell/process Defect (reference)
 
Common lymphoid precursor (CLP) Decreased efficacy of differentiation (4)
Early T cell progenitor (ETP) Decreased efficacy of differentiation; decreased migration into the thymus? (4)
Intrathymic maturation Decreased IL-7 and c-kit production?; reduced VDJ recombination?;
disorganized epithelial architecture; altered selection? (1, 4)
Recent thymic emigrant production, 
migration, and/or peripheral seeding
Reduced generation of new T cells; reduced ability of new T cells to populate periphery? (13)
Naive T cell priming Dendritic cell defects (impaired migration into draining lymph
nodes; impaired antigen uptake and processing?; impaired maturation?)
T cell defects (deficient synapse formation; diminished signaling along TCR and costimulatory pathways; 
reduced IL-2 production) (1, 2, 4)
T cell homeostasis Decrease in CD4/CD8 and naive/memory T cell ratios;
accumulation of dysfunctional memory cells including T cell clonal expansions (1, 2, 4, 16)
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In principle, there is either a limit to the
number of divisions that each cell can
undergo, or the stochastic accumulation
of mutations after 
 
n
 
 divisions (with 
 
n
 
 be-
ing highly variable even within the cells
of the same clone) simply produces rep-
licatively incompetent cells. Regardless,
it is expected that at some point homeo-
static proliferation will not be able to
compensate for the lack of new T cell
production and for their lifelong deple-
tion. Again, this point can be viewed
from the perspective of a single cell, cell
populations, or the whole organism. In
humans, the age of 65 is usually taken as
the beginning of senescence, as this is
when the incidence of severe infectious
diseases becomes elevated. However,
with many pathogens, increased sensitiv-
ity occurs earlier (for example, WNV
and SARS, where increased vulnerabil-
ity starts at, or slightly before, the age of
50). In an attempt to measure the chro-
nological breakdown of homeostasis,
Goronzy’s group recently tested thymic
function, lymphocyte turnover, and T
cell repertoire in humans throughout
middle and old ages (unpublished data
and reference 5). Their results suggest
that discrete time points mark specific
events that lead to a breakdown of ho-
meostatic control in the CD4 T cell
pool. Although there is a log linear de-
cline in thymic output during middle
age (20–60 yr), intense compensatory
proliferation of the remaining naive
CD4, and a final “catastrophic loss” of
naive CD4 T cells with drastic repertoire
constriction, typically occurs in the sev-
enth decade. If confirmed, these stages
would mark periods during which im-
portant measurements can be taken to
elucidate the basis of each event, and also
during which different interventions can
be tested.
Other adverse consequences of com-
pensation for naive T cell loss occur
at the level of cell populations and indi-
vidual cells. One is the accumulation of
cells with a poor ability to replicate in
response to antigen, and these seem to
be particularly prone to arise in response
to chronic persistent infections (11, 21).
Moreover, cell division is one of the
main causes of mutations, which can
lead to cancer (22) or to less severe
transformation as in the case of T and B
cell clonal expansions (23, 24). These
transformed cells take up space at the
expense of other T cells, leading to a
drastic reduction in T cell repertoire di-
versity. Recent evidence suggests that
they are part of a vicious circle that can
lead to impaired immune responses (25).
Therefore, compensatory homeostatic
mechanisms perform critical functions
but are also eventually exhaustible, as
witnessed by their association with new
risks of malfunction and disease (6, 25)
 
Making new T cells in an old organism: 
who’s naive and who’s young now?
 
The recent plethora of information on
T cell homeostasis has raised numerous
questions regarding aging of T cell
compartment, one of which was ele-
gantly answered in this issue by Haynes
et al. (13). These authors asked, if naive
cells can divide many times and remain
naive for many years, are they different
from cells that arise in an old organism
but are young as measured by the time
since their egress from the thymus?
Can, in fact, newly generated T cells be
functional in old mice? Using anti-
body-mediated depletion and/or bone
marrow chimeras, the authors showed
that newly generated T cells in old
mice apparently function normally and
mount vigorous responses to primary
immunization. The results were con-
firmed in both the TCR transgenic and
wild-type mouse models, adding physi-
ological relevance to this important ob-
servation. If confirmed, these results
would bode well for the attempts to in-
crease thymic production and/or im-
prove survival and maintenance of na-
ive T cells (for review see reference
26). At this point, however, there are
many outstanding questions stemming
from this work. For how long can the
new T cells maintain their youthful
function? Is there a barrier to the influx
of new T cells imposed by old T cells
or old microenvironment in the recon-
stituted animal? Although the new cells
were shown to function well, are they
equal to the ones in young animals
with regard to immune defense (for ex-
ample, do they protect equivalently in
a challenge experiment)? Answering
these questions will be both interesting
and challenging, and, along with test-
ing of other experimental treatments,
should pave way to targeted therapies
for immunosenescence in the interme-
diate and long term.
 
Implications for therapy and vaccine 
design
 
The above discussion stresses the ne-
cessity to identify ways to ameliorate
and treat the underlying causes of im-
munosenescence. Such attempts have
multiplied in recent years. Table II lists
 
Table II.
 
Selected experimental treatments to improve T cell immune function in aging
 
Treatment Target Result (reference)
 
Deglycosylation of T cell
surface molecules in mice 
CD43, CD45 and
other surface molecules
Improved signaling, proliferation and
cytokine secretion in both old and young (28, 29)
Treatment with vitamin
E in elderly humans 
Cell membrane fluidity
and oxidative stress 
Reduced incidence of respiratory
infections in the elderly (30)
Addition of costimulation in mice
(immune adjuvants or
costimulatory antibodies) 
Innate immunity/costimulatory pathways Increased CD4 T cell proliferation
and cytokine production (31)
Caloric restriction in mice and primates  Cellular—naive T cell maintenance,
T cell signaling;
molecular target not known
Mice: Improved CTL function and antigen presentation (32)
Primates: improved naive T cell maintenance and
function (unpublished data)
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a few examples of studies addressing
cellular and molecular basis of selected
treatments to improve T cell function
Treatments aimed at improving thymic
output and/or function are reviewed in
references 4, 26, and 27. Those show-
ing promising results will undoubtedly
be pursued further. Unfortunately, there
are very few treatments that are both
clinically applicable and efficacious,
mandating additional research efforts to
improve this outlook. Manipulation of
cytokines critical to T cell homeostasis
(IL-7 and IL-15) is likely to be high on
that list.
An overlapping and concurrent but
separate line of research is aimed at im-
proving immune responses to vac-
cination in the elderly population. A
fundamental question whether some
vaccines need to be reengineered, and
whether others can be modified, still
needs to be answered. Improvement of
CD4 T cell function with the use of
adjuvants has shown some promise in
rodents (31), however translation of
these findings into humans is uncertain.
Similarly, supplementing vaccines with
DNA constructs encoding cytokines
and/or costimulatory molecules can
improve results of priming in adult
mice, but that strategy has shown little
promise in humans due to problems
with both the delivery methods and
differences between mice and humans.
Regardless, IL-12 and IL-18 appear to
be the prime candidates for vaccine op-
timization. Another strategy would be
to optimize recognition of vaccine com-
ponents by the innate immune system.
For such strategies to be effective,
however, it will be important to dissect
the most important and the primary
points of intervention and the extent to
which these points can be influenced,
allowing us to rationally design treat-
ments and vaccines for the elderly.
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